The United States Food and Drug Administration (US FDA) has inspected Aurobindo Pharma’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from May 2, 2022 to May 10, 2022. At the end of the inspection, the company has been issued a 'Form 483' with six observations. The company will respond to the USFDA within the stipulated timeline and work closely with USFDA to close the observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
